- Home
- HRMY
as 01-17-2025 4:00pm EST
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 2.0B | IPO Year: | 2020 |
| Target Price: | $55.00 | AVG Volume (30 days): | 593.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.11 | EPS Growth: | -14.80 |
| 52 Week Low/High: | $28.14 - $41.61 | Next Earning Date: | 02-20-2025 |
| Revenue: | $681,879,000 | Revenue Growth: | 25.83% |
| Revenue Growth (this year): | 24.79% | Revenue Growth (next year): | 19.00% |
Stock Insider Trading Activity of Harmony Biosciences Holdings Inc. (HRMY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Jan 15 '25 | Sell | $37.01 | 10,507 | $388,840.95 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Jan 13 '25 | Sell | $37.04 | 7,180 | $265,946.48 | 0 | |
| Marshman Fund Trust II | HRMY | 10% Owner | Nov 1 '24 | Sell | $30.30 | 4,600,000 | $139,391,500.00 | 6,651,120 | |
| Valor IV Pharma Holdings, LLC | HRMY | 10% Owner | Nov 1 '24 | Sell | $30.30 | 4,600,000 | $139,391,500.00 | 6,618,033 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Oct 29 '24 | Sell | $40.47 | 21,496 | $870,018.36 | 0 |
Latest Harmony Biosciences Holdings Inc. News
HRMY Breaking Stock News: Dive into HRMY Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Why Harmony Biosciences (HRMY) Might be Well Poised for a Surge
Zacks
4 days ago
How Much Upside is Left in Harmony Biosciences (HRMY)? Wall Street Analysts Think 39.48%
TipRanks
4 days ago
Harmony Biosciences price target raised to $32 from $31 at BofA
Argus Research
4 days ago
HRMY: Raising target price to $38.00
Zacks
4 days ago
HRMY or RGEN: Which Is the Better Value Stock Right Now?
Zacks
5 days ago
Are Investors Undervaluing Genmab (GMAB) Right Now?
Insider Monkey
5 days ago
Why Harmony Biosciences (HRMY) Is the Top Small Cap Stock to Buy with the Highest Upside Potential
Investor's Business Daily
5 days ago
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Compare HRMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRMY Harmony Biosciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.